Q&A
iPC Healthcare Investment Sleeve Portfolio 1
INTRODUCTION:
The compartment iPC Healthcare Investment Sleeve Portfolio 1 (2025) has exclusive holdings of several drug IN-LICENSED products to move through the new drug applications (505 b2s or 505 b1s) and extremely complex generics. The portfolio has been constructed with synergies between the underlying pharmaceuticals  within portfolio are Inhalations, Long Acting Injectables and other complex injectables.
Management Team with best-in class technically proven solutions
Proven Team:Â Leadership +100Â years, with deep respect in the scientific community through invited lectures, international patents, peer-reviewed publications, and a highly regarded book chapter on lung cancer.
Â
Proven Track-record:Â Successfully created a drug product portfolio of more than USD 10B. Lead and commercialized 100+ drug products with a cumulative value of USD +50B in US and other leading global markets
iPC Healthcare Investment Portfolio(s) value drivers of drugs within portfolios
